CTMX

CytomX TherapeuticsNasdaqGS:CTMX Stock Report

Market Cap

US$323.8m

7D

-3.9%

1Y

-30.8%

Updated

16 Sep, 2021

Data

Company Financials +
CTMX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CTMX Overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.

Share Price & News

How has CytomX Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTMX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CTMX's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

-3.9%

CTMX

-1.0%

US Biotechs

-0.6%

US Market


1 Year Return

-30.8%

CTMX

24.9%

US Biotechs

33.7%

US Market

Return vs Industry: CTMX underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: CTMX underperformed the US Market which returned 30.7% over the past year.


Shareholder returns

CTMXIndustryMarket
7 Day-3.9%-1.0%-0.6%
30 Day1.6%0.8%1.4%
90 Day-30.8%6.6%5.4%
1 Year-30.8%-30.8%26.5%24.9%35.7%33.7%
3 Year-73.6%-73.6%18.3%12.8%61.2%51.2%
5 Year-70.2%-70.2%46.7%35.2%123.8%99.4%

Long-Term Price Volatility Vs. Market

How volatile is CytomX Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

CytomX Therapeutics Fundamentals Summary

How do CytomX Therapeutics's earnings and revenue compare to its market cap?
CTMX fundamental statistics
Market CapUS$323.83m
Earnings (TTM)-US$64.21m
Revenue (TTM)US$66.42m

4.9x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTMX income statement (TTM)
RevenueUS$66.42m
Cost of RevenueUS$0
Gross ProfitUS$66.42m
ExpensesUS$130.63m
Earnings-US$64.21m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.17
Gross Margin100.00%
Net Profit Margin-96.67%
Debt/Equity Ratio0%

How did CTMX perform over the long term?

See historical performance and comparison

Valuation

Is CytomX Therapeutics undervalued compared to its fair value and its price relative to the market?

2.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CTMX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CTMX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTMX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTMX is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.1x).


Future Growth

How is CytomX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-12.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTMX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTMX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTMX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTMX's revenue (0.3% per year) is forecast to grow slower than the US market (9.5% per year).

High Growth Revenue: CTMX's revenue (0.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CTMX is forecast to be unprofitable in 3 years.


Past Performance

How has CytomX Therapeutics performed over the past 5 years?

-4.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTMX is currently unprofitable.

Growing Profit Margin: CTMX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTMX is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.

Accelerating Growth: Unable to compare CTMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: CTMX has a negative Return on Equity (-49.03%), as it is currently unprofitable.


Financial Health

How is CytomX Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CTMX's short term assets ($271.0M) exceed its short term liabilities ($93.4M).

Long Term Liabilities: CTMX's short term assets ($271.0M) exceed its long term liabilities ($178.1M).


Debt to Equity History and Analysis

Debt Level: CTMX is debt free.

Reducing Debt: CTMX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTMX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CTMX has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 24.4% each year.


Dividend

What is CytomX Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTMX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTMX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Sean McCarthy (54 yo)

10.08yrs

Tenure

US$2,849,850

Compensation

Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since July 2021. He has been the Chief Executive Officer and President of CytomX Therapeutics, Inc. since August 2011 and...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD2.85M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CTMX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: CTMX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.1%.


Top Shareholders

Company Information

CytomX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CytomX Therapeutics, Inc.
  • Ticker: CTMX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$323.830m
  • Shares outstanding: 65.16m
  • Website: https://www.cytomx.com

Number of Employees


Location

  • CytomX Therapeutics, Inc.
  • 151 Oyster Point Boulevard
  • Suite 400
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Biography

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatme...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 04:45
End of Day Share Price2021/09/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.